In last trading session, Tourmaline Bio Inc (NASDAQ:TRML) saw 0.33 million shares changing hands with its beta currently measuring 2.33. Company’s recent per share price level of $16.06 trading at -$0.34 or -2.07% at ring of the bell on the day assigns it a market valuation of $411.82M. That closing price of TRML’s stock is at a discount of -200.81% from its 52-week high price of $48.31 and is indicating a premium of 24.53% from its 52-week low price of $12.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 207.40K if we extend that period to 3-months.
Tourmaline Bio Inc (NASDAQ:TRML) trade information
Upright in the red during last session for losing -2.07%, in the last five days TRML remained trading in the red while hitting it’s week-highest on Monday, 01/27/25 when the stock touched $16.06 price level, adding 11.17% to its value on the day. Tourmaline Bio Inc’s shares saw a change of -20.81% in year-to-date performance and have moved -8.44% in past 5-day. Tourmaline Bio Inc (NASDAQ:TRML) showed a performance of -20.02% in past 30-days. Number of shares sold short was 2.33 million shares which calculate 11.16 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 50 to the stock, which implies a rise of 67.88% to its current value. Analysts have been projecting 50 as a low price target for the stock while placing it at a high target of 50. It follows that stock’s current price would drop -211.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -211.33% for stock’s current value.
Tourmaline Bio Inc (TRML) estimates and forecasts
Statistics highlight that Tourmaline Bio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -4.86% of value to its shares in past 6 months, showing an annual growth rate of 66.29% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19.23% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 67.11% while estimates for its earnings growth in next 5 years are of 20.28%.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 646.41 shares of worth $10.38 million or 2.52% of the total outstanding shares. The later fund manager was in possession of 641.22 shares on Nov 30, 2024 , making its stake of worth around $10.3 million in the company or a holder of 2.50% of company’s stock.
